Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2008 2
2009 1
2010 2
2011 3
2012 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G; DITTO-HCV Study Group. Pilli M, et al. Gastroenterology. 2007 Oct;133(4):1132-43. doi: 10.1053/j.gastro.2007.06.059. Epub 2007 Jul 3. Gastroenterology. 2007. PMID: 17919489 Clinical Trial.
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232. PLoS One. 2011. PMID: 21390311 Free PMC article. Clinical Trial.
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.
Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ; DITTO-HCV Study Group. Bezemer G, et al. BMC Gastroenterol. 2012 Jan 31;12:11. doi: 10.1186/1471-230X-12-11. BMC Gastroenterol. 2012. PMID: 22292521 Free PMC article. Clinical Trial.
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Romero AI, et al. J Infect Dis. 2006 Oct 1;194(7):895-903. doi: 10.1086/507307. Epub 2006 Aug 29. J Infect Dis. 2006. PMID: 16960776 Clinical Trial.
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. Zeuzem S, et al. J Hepatol. 2005 Aug;43(2):250-7. doi: 10.1016/j.jhep.2005.05.016. J Hepatol. 2005. PMID: 16082736 Clinical Trial.
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Hepatology. 2006 Dec;44(6):1617-25. doi: 10.1002/hep.21407. Hepatology. 2006. PMID: 17133471 Clinical Trial.
13 results